The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database

References

• Akash MSH, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2018 Jan;119(1):105–110.
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Feingold KR. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy (Dordrecht, Netherlands). 1991;3(2):143–158.
   PubMedGoogle Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219.
   PubMed Web of Science ®Google Scholar
• Wasko MC, Kay J, Hsia EC, et al. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken). 2011 Apr;63(4):512–521.
   PubMed Web of Science ®Google Scholar
• Wu MY, Yu CL, Yang SJ, et al. Change in body weight and body mass index in psoriasis patients receiving biologics: a systematic review and network meta-analysis. J Am Acad Dermatol. 2020 Jan;82(1):101–109.
   PubMed Web of Science ®Google Scholar
• Issa M, Weber LR, Shidham SV, et al. Infliximab significantly increases proportion of overweight/obese Crohn’s disease patients receiving long term maintenance therapy. Gastroenterology. 2006;130:A209.
   Web of Science ®Google Scholar
• Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine. 2006 Feb;29(1):109–118.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Brewer HB Jr., Cleeman JI, et al. Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):e13–8.
   PubMed Web of Science ®Google Scholar
• Liu Y, Hazlewood GS, Kaplan GG, et al. Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2017 Feb;69(2):157–165.
   PubMed Web of Science ®Google Scholar
• Dai ZH, Xu XT, Ran ZH. Associations between obesity and the effectiveness of anti-tumor necrosis factor-α agents in inflammatory bowel disease patients: a literature review and meta-analysis. Ann Pharmacother. 2020 Aug;54(8):729–741.
   PubMed Web of Science ®Google Scholar
• Singh S, Proudfoot J, Xu R, et al. Obesity and response to infliximab in patients with inflammatory bowel diseases: pooled analysis of individual participant data from clinical trials. Am J Gastroenterol. 2018 Jun;113(6):883–889.
   PubMed Web of Science ®Google Scholar
• Klaasen R, Wijbrandts CA, Gerlag DM, et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheumatism. 2011 Feb;63(2):359–364.
   PubMed Web of Science ®Google Scholar
• Carnovale C, Mazhar F, Arzenton E, et al. Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®. Expert Opin Drug Saf. 2019 Nov;18(11):1099–1108.
   PubMed Web of Science ®Google Scholar
• De Germay S, Bagheri H, Despas F, et al. Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study. Rheumatology (Oxford). 2020 Sep 1;59(9):2360–2367.
   PubMed Web of Science ®Google Scholar
• Pellegrino P, Carnovale C, Borsadoli C, et al. Two cases of hallucination in elderly patients due to a probable interaction between flu immunization and tramadol. Eur J Clin Pharmacol. 2013 Aug;69(8):1615–1616.
   PubMed Web of Science ®Google Scholar
• Pellegrino P, Carnovale C, Perrone V, et al. No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus. Eur J Epidemiol. 2013 Aug;28(8):705–707.
   PubMed Web of Science ®Google Scholar
• Carnovale C, Mosini G, Gringeri M, et al. Interaction between paracetamol and lamotrigine: new insights from the FDA adverse event reporting system (FAERS) database. Eur J Clin Pharmacol. 2019 Sep;75(9):1323–1325.
   PubMed Web of Science ®Google Scholar
• Mazhar F, Battini V, Pozzi M, et al. Hyponatraemia following antipsychotic treatment: in-silico pharmacodynamics analysis of spontaneous reports from the US food and drug administration adverse event reporting system database and an updated systematic review. Int J Neuropsychopharmacol. 2021 Feb 12. DOI:https://doi.org/10.1093/ijnp/pyab005.
   Google Scholar
• Mazhar F, Pozzi M, Gentili M, et al. Association of hyponatraemia and antidepressant drugs: a pharmacovigilance-pharmacodynamic assessment through an analysis of the US food and drug administration adverse event reporting system (FAERS) database. CNS Drugs. 2019 Jun;33(6):581–592.
   PubMed Web of Science ®Google Scholar
• The US Food and Drug Administration (FDA). Adverse Event Reporting System (FAERS); 2020. [2020 Jul 30]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-adverse-event-reporting-system-faers
   Google Scholar
• Carnovale C, Mazhar F, Pozzi M, et al. A characterization and disproportionality analysis of medication error related adverse events reported to the FAERS database. Expert Opin Drug Saf. 2018 Dec;17(12):1161–1169.
   PubMed Web of Science ®Google Scholar
• Fescharek R, Kübler J, Elsasser U, et al. Medical dictionary for regulatory activities (MedDRA). Int J Pharm Med. 2004;18(5):259–269.
   Google Scholar
• Cornelius VR, Sauzet O, Evans SJ. A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data. Drug Saf. 2012 Jul 1;35(7):599–610.
   PubMed Web of Science ®Google Scholar
• Kobayashi T. [Comparative study of the time period between the initiation of various interferon therapies and the onset of suicide- or diabetes-related side effect]. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyujo Hokoku = Bullet Natl Inst Health Sci. 2013;131:45–49.
   Google Scholar
• Sauzet O, Carvajal A, Escudero A, et al. Illustration of the Weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013 Oct;36(10):995–1006.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, et al. Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis. Ann Rheum Dis. 2008 Nov;67(11):1644–1646.
   PubMed Web of Science ®Google Scholar
• Karagiozoglou-Lampoudi T, Trachana M, Agakidis C, et al. Ghrelin levels in patients with juvenile idiopathic arthritis: relation to anti-tumor necrosis factor treatment and disease activity. Metabolism. 2011 Oct;60(10):1359–1362.
   PubMed Web of Science ®Google Scholar
• Chen CY, Tsai CY, Lee PC, et al. Long-term etanercept therapy favors weight gain and ameliorates cachexia in rheumatoid arthritis patients: roles of gut hormones and leptin. Curr Pharm Des. 2013;19(10):1956–1964.
   PubMed Web of Science ®Google Scholar
• Soubrier M, Pereira B, Frayssac T, et al. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience. Int J Rheum Dis. 2018 Nov;21(11):1924–1932.
   PubMed Web of Science ®Google Scholar
• Peluso I, Palmery M. The relationship between body weight and inflammation: lesson from anti-TNF-α antibody therapy. Hum Immunol. 2016 Jan;77(1):47–53.
   PubMed Web of Science ®Google Scholar
• Mazhar F, Battini V, Pozzi M, et al. Changes in Anthropometric Parameters After Anti-TNFα Therapy in Inflammatory Bowel Disease: a Systematic Review and Meta-analysis. Curr Atheroscler Rep. 2020 Oct;34(5):649–668.
   Google Scholar
• Haas L, Chevalier R, Major BT, et al. Biologic agents are associated with excessive weight gain in children with inflammatory bowel disease. Digestive Diseases and Sciences. 2017 Nov;62(11):3110–3116.
   PubMed Web of Science ®Google Scholar
• Christian KE, Russman KM, Rajan DP, et al. Gender differences and other factors associated with weight gain following initiation of infliximab: a post hoc analysis of clinical trials. Dig Dis Sci. 2020 Jan 1;26(1):125–131.
   Google Scholar
• Lepp J, Höög C, Forsell A, et al. Rapid weight gain in infliximab treated Crohn’s disease patients is sustained over time: real-life data over 12 months. Scand J Gastroenterol. 2020 Dec;55(12):1411–1418.
   PubMed Web of Science ®Google Scholar
• Toussirot É, Mourot L, Dehecq B, et al. TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study. Eur J Nutr. 2014 Apr;53(3):951–961.
   PubMed Web of Science ®Google Scholar
• Marouen S, Barnetche T, Combe B, et al. TNF inhibitors increase fat mass in inflammatory rheumatic disease: a systematic review with meta-analysis. Clin Exp Rheumatol. 2017 Mar-Apr;35(2):337–343.
   PubMed Web of Science ®Google Scholar
• van den Oever IAM, Baniaamam M, Simsek S. The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis. Rheumatology International. 2021 Feb;41(2):319–328.
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Hosomi K, Yokoyama S, et al. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. Journal of Clinical Pharmacy and Therapeutics. 2020 Feb;45(1):65–71.
   PubMed Web of Science ®Google Scholar
• D’Haens GR. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. J Clin Pharm Ther. 2021 Jul;70(7):1396–1405.
   Google Scholar
• Van Deventer S, Kivelevitch D, Mansouri B, et al. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Gut. 2014;8:169–182.
   Google Scholar
• Toussirot E. The interrelations between biological and targeted synthetic agents used in inflammatory joint diseases, and obesity or body composition. Rheumatol Int. 2020 Mar 13;10(3):107.
   Google Scholar
• Gremese E, Carletto A, Padovan M, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken). 2013 Jan;65(1):94–100.
   PubMed Web of Science ®Google Scholar
• Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PloS One. 2018;13(5):e0195123.
   PubMed Web of Science ®Google Scholar
• Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012 Sep 4;126(10):1301–1313.
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Mavridis AK, Vasakos S, et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005 May;64(5):765–766.
   PubMed Web of Science ®Google Scholar
• Tripolino C, Ciaffi J, Pucino V, et al. Insulin Signaling in Arthritis. Front Immunol. 2021;12:672519.
   PubMed Web of Science ®Google Scholar
• Végh E, Kerekes G, Pusztai A, et al. Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis. Rheumatol Int. 2020 Mar;40(3):427–436.
   PubMed Web of Science ®Google Scholar
• Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis. 2005 Feb;64(2):303–305.
   PubMed Web of Science ®Google Scholar
• Ajala ON, Everett BM. Targeting Inflammation to reduce residual cardiovascular risk. Current Atherosclerosis Reports. 2020 Sep 3;22(11):66.
   PubMed Web of Science ®Google Scholar
• Nikolaus S, Raedler A, Kühbacker T, et al. Mechanisms in failure of infliximab for Crohn’s disease. Lancet. 2000 Oct 28;356(9240):1475–1479.
   PubMed Web of Science ®Google Scholar
• Faillie JL. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019 Apr;74(2):225–232.
   PubMed Web of Science ®Google Scholar